Santa Ana Bio

Based in California, US, and founded by Peter Emtage (CEO) in 2022, Santa Ana Bio, Inc. operates as a biotechnology company that develops pharmaceutical medicines for patients with autoimmune and inflammatory diseases. In June 2024, Santa Ana Bio, Inc. The precision immunology company focuses on developing targeted therapies by leveraging multi-omics platforms and advanced antibody engineering. Santa Ana has established a pipeline of novel therapeutics, including monoclonal antibodies, bi-specific antibodies, and antibody-drug conjugates (ADCs). Notable programs include SAB01, a bi-specific antibody that conditionally blocks the c-Kit receptor to treat allergic diseases with reduced toxicity; SAB03, which targets PD-1 to treat rheumatoid arthritis by eliminating pathogenic T cells; and SAB05, an ADC program that harnesses glucocorticoid efficacy while minimizing side effects. Additionally, Santa Ana Bio's proprietary SIERRA platform integrates multi-modal patient data to gain deep insights into the cellular and immune pathways underlying immune-mediated diseases. This platform enables the rapid advancement of therapeutic programs from concept to clinical trials, ensuring precise targeting of disease pathways and minimizing broad immune suppression.

1. Series B

   May 16, 2024

   Amount

   $20M

   Investors

   Locked

2. Series A

   Feb 14, 2023

   Amount

   $35M

   Investors

   Locked